Ovid Therapeutics Inc. (OVID): Shareholders' Equity
$130.66M
As of 2025-12-31
$209.89M
As of 2026-06-30
-0.4%
3-year compound annual growth
+24.5%
5-year compound annual growth
+6.7%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $130.66M | +91.5% | 2026-03-18, Balance as of period end |
| 2024-12-31 | $68.23M | -22.3% | 2026-03-18, Balance as of period end |
| 2023-12-31 | $87.80M | -33.6% | 2025-03-11, Balance as of period end |
| 2022-12-31 | $132.27M | -26.4% | 2024-03-08, Balance as of period end |
| 2021-12-31 | $179.75M | +312.0% | 2023-03-13, Balance as of period end |
| 2020-12-31 | $43.63M | -37.7% | 2022-03-15, Balance as of period end |
| 2019-12-31 | $70.02M | +80.4% | 2021-03-15, Balance as of period end |
| 2018-12-31 | $38.81M | -53.5% | 2020-03-11, Balance as of period end |
| 2017-12-31 | $83.44M | +69.3% | 2019-03-07, Balance as of period end |
| 2016-12-31 | $49.29M | -27.6% | 2018-03-29, Balance as of period end |
| 2015-12-31 | $68.07M | n/a | 2018-03-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | $130.66M | +91.5% |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | $136.31M | +159.7% |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | $581.76M | -22.9% |
| Immunome Inc. (IMNM) | 2025-12-31 | $634.34M | +250.1% |
| Adagene Inc. (ADAG) | 2025-12-31 | $35.35M | -30.0% |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | $26.50M | -53.7% |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | $103.08M | -33.7% |
| Coya Therapeutics, Inc. (COYA) | 2025-12-31 | $43.03M | +8.7% |
| Korro Bio, Inc. (KRRO) | 2025-12-31 | $51.44M | -67.9% |
Compare OVID, WHWK, XENE, IMNM side by side · Screen every company in Pharmaceutical Preparations ↗